Metabolic and immunological consequences of glycation of low density lipoproteins.
Witztum
J L
JL
Department of Medicine, University of Calif., San Diego, La Jolla 92093.
Koschinsky
T
T
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001798:Blood Proteins / Q000276:immunology; D003920:Diabetes Mellitus / Q000378:metabolism; D017127:Glycation End Products, Advanced; D006031:Glycosylation; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology / Q000378:metabolism*; D008239:Lysine / Q000031:analogs & derivatives / Q000276:immunology; D011973:Receptors, LDL / Q000378:metabolism; D000093844:Glycated Proteins
D001323:Autoantibodies; D001798:Blood Proteins; D017127:Glycation End Products, Advanced; D008077:Lipoproteins, LDL; D008239:Lysine; D011973:Receptors, LDL; C025615:glucosylated serum protein; C031797:glycated lipoproteins, LDL; D000093844:Glycated Proteins; C034247:glucitollysine